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Abstract
Background: Cigarette smoke with its toxic ingredients leads to chronic inflammations in the airways.
Objectives: In this study, the effect of cigarette smoke on the levels of inflammatory markers, interleukin-6 (IL-6), 
interleukin-8 (IL-8), and tumor necrosis factor-alpha (TNF-α) in induced sputum was investigated.
Materials and Methods: Twenty patients with chronic obstructive pulmonary disease (COPD) (group I), 20 healthy 
smokers (group II), and 20 healthy nonsmokers (group III) were included in the study. The levels of IL-6, IL-8, and 
TNF-α in induced sputum were measured in these groups, and comparison analysis between the groups and correlation 
analysis for smoking load (pack-years) and spirometric parameters were performed.
Results: Mean age of the patients in groups I, II, and III were 61.2 ± 1.7, 58.2 ± 1.6, and 59.1 ± 5.4 years, respectively 
(P > 0.05). Smoking loads of group I and group II were 38.6 ± 2.1 and 29.5 ± 2.3 pack-years, respectively (P < 0.05). All 
cytokine levels were significantly higher in group I than groups II and III (P < 0.05). In addition to this, mean cytokines 
levels were significantly higher in group II than group III (P < 0.05). Smoking load of group II subjects was positively 
correlated with IL-6, IL-8, and TNF-α in induced sputum (P < 0.05).
Conclusions: We found that inflammatory marker levels in induced sputum were significantly higher in COPD patients 
and smokers than nonsmokers. Moreover, there was a moderate positive correlation between IL-6, IL-8, and TNF-α 
levels and smoking load in the healthy smokers. We think that further studies are needed to determine whether higher 
levels of cytokine levels in sputum might be helpful in predicting the healthy smokers who will develop COPD in future.
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Introduction
Cigarette smoking is by far the most commonly encountered 
risk factor for chronic obstructive pulmonary disease 
(COPD). Cigarette smokers have a higher prevalence of 
respiratory symptoms and lung function abnormalities, 
a greater annual rate of decline in FEV1 and a greater 
COPD mortality rate than nonsmokers. These differences 
between smokers and nonsmokers show direct correlation 
with the smoking load (pack-years). Patients should be 
identified as early in the course of the disease as possible and 
certainly before the end stage of the illness when disability 
is substantial. Access to spirometry is key to the diagnosis 
of COPD. However, the benefits of community-based 
spirometric screening, of either the general population or 
smokers, are still unclear. Therefore, it is necessary to find 
sensible parameters to detect early lung alterations due 
to chronic tobacco smoke exposure. Long-term cigarette 
smoking is associated with a persistent inflammatory 
response in the lung that leads to tissue injury and 
dysfunction. Induced sputum are validated noninvasive 
techniques for assessing respiratory inflammation. This 
approach could enable an early identification of subgroups 
of healthy smokers at higher risk for tobacco-induced lung 
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damage and prompt planning of secondary prevention 
strategies.[1]
Cytokines are extracellular signaling proteins formed 
by various cells types in the body. Interleukin-6 (IL-6) 
is a proinflammatory cytokine and lymphokine. IL-6 is 
produced by almost all different types of lung cells including 
endothelial cells, airway epithelial cells, fibroblasts, and, 
most notably, alveolar macrophages. IL-6 is thought to 
play a role in all types of acute lung inflammation through 
its stimulatory effects on lymphocytes and the acute phase 
response. Interleukin-8 (IL-8), a CXC chemokine, is an 
important neutrophil chemoattractant and activator. Tumor 
necrosis factor-alpha (TNF-α) is also proinflammatory 
cytokine. These cytokines have been shown to be important 
markers of inflammation and play key roles in the persistence 
of inflammatory process in COPD.[2,3]
It was previously showed that COPD patients had higher 
serum levels of TNF-α, IL-8, and IL-6 than healthy control 
subjects.[4] It was also showed that TNF-α, IL-6, and IL-8 
levels were found in increased amounts in the sputum and 
exhaled breath of patients with COPD, particularly during 
exacerbations.[5-7]
Chronic inflammation in the airways of individuals who 
smoke persists even after smoking cessation. We aimed 
to show whether COPD patients who continue to smoke 
has higher levels of IL-6 level, IL-8 level, and TNF-α than 
current healthy smokers and nonsmokers. We also aimed to 
analyze whether cytokine levels in induced sputum show any 
relationship with smoking load and the severity of airway 
obstruction.
Materials and Methods
Twenty current smokers with stable COPD (group I) and 40 
age-matched healthy control subjects [20 current smokers 
(group II) and 20 nonsmokers (group III)] were included in 
the study. Twenty healthy individuals were taken as control 
group in study. Their age and sex characteristics were similar 
to the groups. The study was carried out at the outpatient 
clinics of pulmonary medicine, Turgut Ozal Research Center 
of Inonu University, Malatya, Turkey. The study protocol 
was approved by the Ethics Committee of the center, and 
informed consent was obtained from the all participants. 
Pulmonary function tests (PFT) were performed in all cases 
using the Vmax 22 device (Sensor Medics, Yorba Linda, CA, 
USA). In clinically compatible patients, COPD was defined 
as a postbronchodilator FEV1/FVC ratio of <70%.
[1]
All COPD patients who were admitted to our outpatient 
clinics for an acute exacerbation were exclusion criteria in 
the study. All COPD patients were included in the study and 
were treated in a standard inhaled bronchodilators (inhaled 
long-acting antimuscarinic [tiotropium bromide 18 µg per 
capsule, one inhalation once daily], inhaled corticosteroid 
and long-acting β agonist [budesonide 160/320 µg/inhalation 
and formoterol fumorate dihydrote 4.5/9 µg/inhalation, one 
inhalation twice daily], inhaled short-acting bronchodilator 
[albuterol sulfate 100 µg/inhalation and ipratropium 
bromide 20 µg/inhalation, if required] and if supplemental 
oxygen. They were no medications except for COPD. The 
COPD patients were not enrolled at all if they had an 
exacerbation or utilization of systemic form of corticosteroid 
preparations (oral or intravenous injection therapy) within 
1 month prior to the study entry. Antibiotics were not 
used where signs of bacterial infection existed. Since our 
long-term treatment policy for the patients with COPD 
did not include administration of maintenance oral 
corticosteroids, we did not see any COPD patients utilizing 
oral or intravenous corticosteroid therapy during the study 
period in the region. COPD patients admitted with specific 
reasons like pneumonia, pulmonary emboli, congestive 
heart failure, lung cancer, etc., were not included. All 
subjects had no other pulmonary disease including asthma, 
bronchiectasia, pneumonia, tuberculosis, or lung cancer. 
Additionally, patients with respiratory failure were not 
admitted to the Intensive Care Unit. In addition to this, 
while groups II and III patients were not utilizing any type 
of medication, COPD patients were also not utilizing any 
kind of medication, including theophylline preparations, 
diuretics, mucolytics, antibiotics, etc., other than inhaled 
bronchodilators. Posteroanterior chest films were obtained 
from all patients, and no abnormality was detected in the 
participants other than the patients with COPD. In their 
recent and past medical history, healthy smokers and 
nonsmokers did not describe any disease state which may 
interfere with their pulmonary functions. Smoking history 
[pack-years (number of cigarette packs per day multiplied 
by duration of smoking in years)] was taken from all group I 
and group II subjects.
Induced sputum samples were obtained from the subjects 
by means of ultrasonic nebulizators (Hirtz, Hico-Ultrasonat 
806 EH, Köln-Germany). For this purpose, patients were 
instructed to rinse their mouths with water after inhalation 
of a 3% saline solution for 5-7 minutes, and then asked to 
expectorate deeply for the 2 ml induced sputum samples to 
be collected. After 7 min of nebulization, measurement of 
oxygen saturation and spirometric tests were performed and 
nebulization continued if the FEV1 had not fallen by more 
than 20%. In patients in whom adequate amount of sputum 
sample could not be collected, saline inhalation was repeated 
at the same dose after further 7 min and the procedure 
stopped. The samples that were collected in wide-covered 
sterile 50 cc polypropylene plastic cups were immediately 
transferred to the laboratory after labeling for processing. 
The induced sputum samples were examinated as soon as 
possible within an hour. The sputum samples were prevented 
from contamination with saliva by filtering through 
78 Nigerian Journal of Clinical Practice • Jan-Mar 2013 • Vol 16 • Issue 1
Hacievliyagil, et al.: Airway inflammatory markers
double-layered sterile gauze immediately after collection. 
With the aid of a forceps and spatula approximately 1-1.5 g 
of sputum was taken from each sample and transferred 
into 10 ml sterile polypropylene tubes with predetermined 
weights and reweighed. After the addition of a phosphate 
buffer solution (PBS) that weighed nine times their fresh 
weight, 5-6 pieces of silicone glass beads were introduced 
into each tube and stirred with a vortex for 10 min until 
a homogenized solution was obtained. The solution was 
thereafter subjected to centrifugation at +4°C for 10 min at 
1000 rpm. The resulting supernatant was transported into 
polypropylene tubes in aliquots of 1ml. After the addition 
of 10 ml 100 mM phenyl methyl sulfonyl fluoride (PMSF) 
into each tube, they were covered and turned upside down 
several times to ensure adequate mixing. The supernatant 
deconted off and stored at −70°C.[8,9]
The IL-6, IL-8, and TNF-α levels were measured by the 
chemiluminescence method using an Immulite-1000 
analyzer and special kits (DPC [Diagnostic Product Co., 
CA, USA]). The lower limit of detection for these assays was 
5 pg/ml for IL-6, 2 pg/ml for IL-8, and 5 pg/ml for TNF-α. 
The interassay and intraassay coefficients of variation of the 
all assays were less than 10%.
All statistical analyses were performed using SPSS 13.0 
for Windows (SPSS, Inc., Chicago, IL, USA). Group data 
were expressed as means ± SEM. The data were tested for 
normality, non-normal data were transformed. Differences 
between the groups were tested using the Kruskal-Wallis 
test. Correlation between cytokine levels and different 
parameters (smoking load and spirometric parameters) 
was analyzed using Spearman’s rank correlation coefficient. 
A P value < 0.05 was considered statistically significant.
Results
The mean age of the COPD patients (group I), current 
healthy smokers (group II), and nonsmokers (group III) were 
61.2 ± 1.7, 58.2 ± 1.6, and 59.1 ± 5.4 years, respectively 
(P > 0.05). Group I and group II subjects had mean smoking 
load of 38.6 ± 2.1 and 29.5 ± 2.3 pack-years, respectively 
(P = 0.007). Of the COPD patients, 3 subjects fulfilled 
the criteria for GOLD stage I, 6 subjects were GOLD stage 
II, 10 subjects were GOLD stage III, and 1 subjects were 
GOLD stage IV.
The PFT results for groups are shown in Table 1. Although 
group II patients are healthy subjects, their spirometric 
values were significantly lower than the group III subjects. 
However, their spirometric values were found within the 
normal range. Patients with COPD and other participants 
did not report any adverse event or worsening dyspnea upon 
induction of sputum. No significant change in FEV1 before 
and after the inhalation of hypertonic saline occurred.
The levels of IL-6 in the induced sputum were 
393.6 ± 107.2 pg/ml for group I, 88.5 ± 23.8 pg/ml for 
group II, and 7.4 ± 1.3 pg/ml for group III. The mean 
induced sputum IL-8 levels for groups I, II, and III were 
6541.7 ± 861.0, 2717.4 ± 632.7, and 385.9 ± 30.1 pg/ ml, 
respectively. TNF-α levels in the induced sputum were 
found to be 90.8 ± 19.6, 36.3 ± 5.7, and 13.7 ± 0.4 pg/ ml 
for groups I, II, and III, respectively. Comparison of all 
cytokine levels in induced sputum yielded statistically 
significant results between groups (P < 0.001). Smoking 
load of group II subjects was positively correlated with IL-6, 
IL-8, and TNF-α in induced sputum (r = 0.567, P = 0.009; 
r = 0.646, P = 0.002; r = 0.491, P = 0.028, [Figures 1–3]).
Discussion
Cigarette smoking is accepted to be the most important 
cause of COPD, but only some smokers will develop 
clinically overt disease. Probably, the inflammation caused 
by cigarette smoke interacts with other host and/ or 
environmental factors to produce the excess decline in lung 
function which results in COPD.[1] There are numerous 
studies investigating the relationship between cigarette 
smoke and airway inflammation.[10,11] In the present study, 
all cytokine levels in induced sputum were found higher in 
COPD patients than healthy smokers and nonsmokers, as 
well as these levels was found higher in healthy smokers 
than nonsmokers. In addition to these, the levels of IL-6, 
IL-8, and TNF-α were positively correlated with smoking 
load (pack-years) only in healthy smoker group but not in 
COPD group.
Cigarette smoke activates alveolar macrophages and 
epithelial cells to release inflammatory mediators such 
as TNF-α and IL-8.[12,13] Mio et al. showed that bronchial 
epithelial cells isolated from major bronchi responded to 
tobacco smoke to release IL-8.[14] Takizawa et al. found 
high levels of IL-8 mRNA and spontaneous release of IL-8 
Figure 1: Correlation analysis between IL-6 levels in induced 
sputum and smoking load in group 2 (r = 0.567, P	=	0.009)
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protein in small-airway epithelial cells in smokers compared 
with that in nonsmokers.[15] Wang et al. measured the 
induced sputum IL-6, IL-8, and TNF-α levels in 20 patients 
with stable COPD and compared them with smoking and 
nonsmoking control groups.[16] While the IL-8 and TNF-α 
levels in the COPD group were found to be significantly 
higher than the smoking and nonsmoking groups, IL-8 level 
in the smoking group was also found significantly higher 
than the nonsmoking group. The IL-6 levels, however, did 
not show any significant differences between the groups. 
Similarly, we also found the same results regarding IL-8 
and TNF-α levels with one difference that IL-6 levels were 
also significantly higher in the smoking groups than the 
nonsmoking group and in the COPD group than the others. 
On the other hand, we found that healthy smoker group’s 
inflammatory markers were higher from the nonsmoker 
group but lower from the COPD group. It is unclear if the 
IL-6, IL-8, and TNF- α levels in COPD and healthy smoking 
group were also higher before they started to smoke or they 
had given a higher inflammatory response to smoking. 
Like most of the previous studies our study was also a 
cross sectional. To understand this, long-term prospective 
investigations should be done.
There are numerous studies in the literature which 
investigated the relationship between cytokine levels in the 
airways and spirometric parameters. Yamamoto et al. reported 
a negative correlation between the IL-8 levels in induced 
sputum and the FEV1/FVC ratio in COPD patients.
[17] In 
another study, FEV1 was found to be inversely correlating 
with IL-6 and IL-8 concentrations in bronchoalveolar 
lavage (BAL) fluid.[18] In addition to these, Kanazawa et al. 
found a positive correlation between the serum IL-8 level 
and the annual rate of fall in FEV1 ratio.
[19] However, in a 
similar way with the study by Bhowmik et al., we also could 
not establish any relationship between cytokine levels in 
induced sputum and spirometric parameters in our study.[5] 
We think that methodological variations between the studies 
mentioned above and limited number of participants in each 
study might have displayed these different results. The 
relationship of cytokine levels in the airways with smoking 
load has been vigorously investigated by several clinicians. 
Table 1: The comparison of general characteristics, spirometric parameters, and cytokines levels in induced 
sputum between the groups
Group 1 (COPD) Group 2 (healthy smokers) Group 3 (healthy nonsmokers) P
Number of subjects 20 20 20
Age (years) 61.2±1.7 58.2±1.6 59.1±5.4 0.218
Gender (M/F) 17/3 16/4 14/6 0.503
Smoking load (pack-years) 38.6±2.1 29.5±2.3 - 0.006
FVC (% predicted) 72.5±3.3 85.7±3.6 105.2±2.4 <0.001
FEV1(% predicted) 41.3±2.6 83.1±3.3 101.0±2.5 <0.001
FEV1/FVC (%) 46.7±2.6 82.1±1.0 84.4±1.8 <0.001
FEF 25-75% (% predicted) 17.4±1.8 72.7±3.5 90.5±3.7 <0.001
IL-6 (pg/ml) 393.6±107.2 88.5±23.8 7.4±1.3 <0.001
IL-8 (pg/ml) 6541.7±861.0 2717.4±632.7 385.9±30.1 <0.001
TNF-α (pg/ml) 90.8±19.6 36.3±5.7 13.7±0.4 <0.001
FVC=forced vital capacity, FEV1=forced expiratory volume in the first second, FEF25‑75%=forced expiratory flow during middle half of the FVC, 
IL‑6=Interleukin‑6, IL‑8=Interleukin‑8, TNF‑α=Tumor necrosis factor‑alpha. Data presented as mean±SEM of groups.
Figure 2: Correlation analysis between IL-8 levels in induced 
sputum and smoking load in group 2 (r = 0.646, P	=	0.002)
Figure 3: Correlation analysis between TNF-α levels in induced 
sputum and smoking load in group 2 (r = 0.491, P	=	0.028)
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Bhowmik et al. established a correlation between the 
induced sputum IL-6 level and the smoking load.[5] Takizawa 
et al. found a significant correlation between IL-8 mRNA 
levels and current amount of cigarette smoked.[15] Kanazawa 
et al. found a correlation between the serum IL-8 level and 
the smoking load in patients with emphysema.[19] In our 
study, correlation analysis revealed that there is moderate 
relationship between all relevant cytokine levels and 
smoking load in healthy smokers. Moreover, this relationship 
could not be shown in the COPD group at all. This finding 
is very interesting, and it implies that smoking load might 
be an indicator to predict the smokers who will develop 
COPD in future. Since a severe inflammation in the airways 
of COPD patients is already established and persists and 
progresses in a vicious cycle, cytokine levels are expectedly 
much higher in this group and patient-to-patient variation 
regarding the cytokine levels is not significant. Probably 
due to this fact, cytokine levels in the airways of COPD 
patients did not show any correlation with smoking load. 
Since long-term follow-up was not the scope of our study, we 
could not set any clinically significant cut-off value for the 
relevant cytokines and smoking load which might help to 
predict the healthy smokers in risk. However, we think that 
our findings lend remarkable support for designing further 
studies including long-term follow-up too in their methods.
We believe that our study has several strengths. Sputum 
analysis is used increasingly as a convenient, safe, and 
noninvasive method of assessing airway inflammation, 
both in terms of cellular indices and soluble mediators of 
inflammation. The repeatability, validity, and responsiveness 
of the method have been confirmed. Finally, measurement of 
cytokines in sputum supernatants is used as a research tool, 
but requires standardization of procedures and, generally, 
analytical validation.[8,9,20] In our study, the interassay and 
intraassay coefficients of variation of the all assays were less 
than 10%. In future, smokers will develop COPD that shows 
you have a pretest or marker as cytokines. The findings of 
future large prospective randomized controlled trials could 
provide more definitive evidence.
Some limitations of this study should be emphasized. 
A limitation of this study is that the numbers of COPD 
patients, healthy smokers, and nonsmokers were relatively 
small. Another lacks of present study, this could not be 
verified in our study because characterization of cellular 
components of the sputum was not performed. The lack of 
relationship between cytokines profiles in sputum indicates 
the effects of smoking or smoking cessation.
In conclusion, cytokines levels were found higher in COPD 
patients and in healthy smokers than nonsmokers. In 
addition to this, there was a moderate positive correlation 
between IL-6, IL-8, and TNF- α levels and smoking load in 
the healthy smokers. We foresight that elevated cytokine 
levels in the airways and greater smoking load might help 
the clinicians to predict COPD development in a better way. 
These assays can be used to evaluate IL-6, IL-8, and TNF- α 
levels as a biomarker for lung disease and to monitor clinical 
practice in the healthy smokers and COPD. Further studies 
to explore the relationship between cigarette-smoking 
load and inflammatory responses, cytokines should been 
used evaluated to monitor clinical practice in the healthy 
smokers and COPD.
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